TBL1X

Across TCGA pan-cancer cohorts, TBL1X Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBL1X data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TBL1X Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBL1X expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and HNSC are the cancer types where TBL1X Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	All	0.978	0.611	.001	36	view →
HNSC	OS	Median	II,III,IV	0.225	0.613	.002	21	view →
LUAD	OS	Median	II,III,IV	0.345	0.753	.011	15	view →
LIHC	OS	Median	All	0.105	0.774	.002	12	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBL1X–ACC (DFS)

Open the ACC breakdown →